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Background: Epithelial ovarian cancer (EOC) is still a major gynecologic problem with poor 5 year survival rate due
to distance metastases, despite routine surgery and chemotherapy. The precise underlying molecular mechanisms
that trigger EOC migration and invasion are unclear. Recent studies suggest that the expression of microRNAs is
widely dysregulated in ovarian cancer; and that they have evolved into tumorigenic processes, including cell
proliferation, apoptosis and motility.
Methods: The expression of miR-124 was assessed in clinical ovarian cancer specimens and cell lines using miRNA
qRTPCR. The function of miR-124 on cell migration and invasion was confirmed in vitro through wound healing
assay and transwell assay. Luciferase reporter assay was used to confirm target associations.
Results: We showed that miR-124 is down-regulated in ovarian cancer specimens as well as in cell lines; and that
low-level expression of miR-124 is much lower in highly metastatic ovarian cancer cells and tissues. Meantime,
overexpression of miR-124 dramatically inhibits the motility of ovarian cancer cells in vitro and substantially suppresses
the protein expression of SphK1, reported as an invasion and metastasis-related gene in human cancers, whose
expression is markedly increased in both ovarian cancer cell lines and clinical samples, particularly in two highly
metastasis cells, SKOV3-ip and HO8910pm as well as metastatic ovarian tumor tissues. Furthermore, SphK1 is identified
as a direct target of miR-124, and knock-down of SphK1 in ovarian cancer cells, SKOV3-ip and HO8910pm, could mimic
the inhibition of migration and invasion by miR-124, while re-introduction of SphK1 abrogates the suppression of
motility and invasiveness induced by miR-124 in both cell lines.
Conclusions: Our studies suggest a protective role of miR-124 in inhibition of migration and invasion in the molecular
etiology of ovarian cancer, and a potentially novel application of miR-124 in the regulation of migration and invasion in EOC.
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MicroRNAs (miRNAs) are endogenous non-coding small
RNAs that execute post-transcriptional regulation by
binding to the 3’-UTR of target genes [1-4], function as
either oncogenes or tumor suppressor genes [5]. During
recent years, more and more studies have reported a
functional contribution of specific miRNAs in diverse bio-
logical processes [6-8], including deregulation of miRNAs* Correspondence: qzhao@shsmu.edu.cn; diwen163@163.com
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stated.by acting on their targeted genes in the progression and
tumorgenesis of human cancers [5,9,10].
Ovarian cancer, one of the most common causes of death
in women worldwide, is still a major problem in China over
the past few decades [11-13] with high mortality, which
is mainly due to the fact that more than 70% of patients
are in late-stage, with distant metastases at the time of
diagnosis [2,9]. It is reported that ovarian cancer is associ-
ated with multistep changes in the genome, in particular
the expression and function of various microRNAs
[9,14]. Although a large number of studies have shown
a great potential for the use of microRNA in diagnosis,
prognosis, and therapy in ovarian cancer [15,16], the
precise association between microRNAs and migration
and invasion of ovarian cancer is still relatively unclear.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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[2,10], including miR-124 [2]. MiR-124 was first reported
to be highly expressed in neuronal cells [17], but its tumor-
suppressor activity was significantly down-regulated in
various cancer tissues [8,18-21]. Also, It has been reported
that miR-124 involves in several malignant processes,
including tumor proliferation, Epithelial-mesenchymal
transition (EMT), and angiogenesis [6,19-23]. However,
the expression level and the possible role of miR-124 in
ovarian cancer remain to be explored.
SphK1 (Sphingosine kinase 1), a master kinase that
regulates the balance between ceramide/sphingosine and
S1P levels, mediates cellular behaviors and may determine
cancer progression, including proliferation, migration, and
invasion [24,25]. It has been demonstrated that SphK1
is an important enzyme encoded during neoplastic trans-
formation [25,26]. In addition, SphK1 plays a critical role
in motility and invasion of some cancer cells [27-29].
However, it is unclear whether SphK1 is responsible for
malignant transformation of ovarian cancer.
We aimed to elucidate the involvement of miR-124 and
SphK1 in migration and invasion of ovarian cancer. Our
studies indicated that miR-124 was down-regulated in
ovarian cancer cell lines and clinical samples. Interestingly,
there is a significant correlation between the expression
level of miR-124 and metastasis of ovarian cancer. On
the other hand, our data showed that overexpression of
miR-124 in ovarian cancer cells suppressed cell motility
via SphK1, suggesting that SphK1 was identified as a
direct and functional target for miR-124 in ovarian cancer
progression. Thus, our findings provide valuable informa-
tion toward unveiling the mechanisms of human ovarian
cancer metastasis, and a novel target of potentially effective
clinical therapies in the future.
Methods
Patients and ethics
Eleven malignant ovarian tumor tissues and normal ovarian
tissues (as listed in Table 1) were selected from the archives
of the Department of Obstetrics & Gynecology at Ren Ji
Hospital, Shanghai JiaoTong University School of Medicine
(Shanghai, China). This study was approved by the Institu-
tional Review Board of Ren Ji Hospital, Shanghai JiaoTong
University School of Medicine; and written informed con-
sent was obtained from all patients. All clinical inves-
tigations were conducted according to the principles
expressed in the Declaration of Helsinki.
Cell lines and cell culture
Human ovarian SKOV3, HO8910pm cell lines with high-
metastasis potential [30], HO8910, ES-2 and A2780 were
obtained from Shanghai Institute of Cell Biology, China
Academy of Sciences (Shanghai, China). OVCAR3 and
OV90 were obtained from ATCC. SKOV3-ip1 andSKOV3-ip2 cells were selected from SKOV3 cell. All cells
were cultured in RPMI-1640 medium supplemented with
10% fetal calf serum (GIBCO) in a humidified atmosphere
of 5% CO2 at 37°C [31].Selection of invasive sublines from SKOV3 cell
To select a highly invasive subpopulation, SKOV3 cells
were seeded in a corning 8 μm-pore transwell with Matrigel
(BD Biosciences). After 24 hours, cells that had invaded
to the other side of the transwell membrane were collected,
expanded and then re-seeded into another Matrigel coated
transwell. Such selection rounds for highly invasive cells
were repeated two times.Quantitative PCR and immunoblotting
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. Single-stranded cDNA was synthesized
with the PrimeScript Reagent Kit (Promega, Madison,
WI, USA). Real-time PCR was performed using SYBR
Green PCR Master Mix (Applied Biosystems) on an ABI
7300HT real-time PCR system (Applied Biosystems,
Foster City, CA, USA). Expression data were normalized
to the internal control (U6) and the relative expression
levels were evaluated using the Ct method. Primers for
RT–PCR are listed in Table 2. For the protein expression
analyses, standard Western blotting was carried out and
the antibodies used were SphK1 (H00008877-M01, Abnova,
Taiwan) and β-Actin (CP01, Calbiochem, MA, USA).Transfection of miR-124 or siRNA against SphK1
MiR-124 and the negative control were synthesized by
Genepharma (Shanghai, China). Three siRNA duplex
oligonucleotides fragments against SphK1 gene were synthe-
sized by Ribobio (Guangzhou, China). Oligonucleotides were
transfected with Lipofectamine 2000 reagent (Invitrogen,
Paisley, Scotland, UK) at a concentration of 100 nM. For
proliferation assays, cells were trypsinized 24 h after trans-
fection. For migration, invasion, and western blot assays,
cells were collected 48 h after transfection, as described
previously.Monolayer wounding assay
For monolayer wounding assays, cells were plated in BD
Falcon 24-well tissue culture plates after transfection and
allowed to attach overnight. After serum deprivation for
12 h, confluent monolayers were scratched using a 10-μl
pipette tip and washed once with serum-free medium.
Twenty-four hours later, migration was assessed micro-
scopically, and quantified using Multi Gauge V3.0 soft-
ware (Fujifilm, Tokyo, Japan).
Table 1 Clinical characteristics of women with ovarian cancer
Patient no. Age (year) Grade TNM Stage Ascites Menopause Histological subtype Location
1 51 3 T1cN0M0 Ic + No Mucinous papillary adenocarcinoma —
2 45 - T1N1M0 IIIc - No poorly differentiated carcinoma Right
3 34 1 T1bN0M0 Ib - No Mucinous cystadenocarcinoma Right
4 62 2 T2N0M0 II + Yes Adenocarcinoma Left
5 60 3 T1aN0M1 IV - Yes Serous papillary adenocarcinoma Right
6 39 1 T1bN0M0 Ib - No Mucinous cyst adenocarcinoma Left
7 57 3 T1cN0M0 Ic - Yes Serous adenocarcinoma —
8 49 3 T2aN0M1 IV + Yes Serous adenocarcinoma Left
9 43 - T2aN0M1 IV + No poorly differentiated carcinoma Right
10 73 - T3cN1M1 IV + Yes poorly differentiated carcinoma Right
11 50 2 T3N1M0 IIIc - No Serous adenocarcinoma Left
12 47 - - - - - - Right
13 55 - - - - - - Right
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Cell migration was determined in Corning transwell insert
chambers as described previously [31]. Cells suspended in
200-μl serum-free 1640 medium were placed into the
upper chamber of the insert with or without Matrigel.
After 24 h of incubation, cells remaining on the upper
membrane were carefully removed. Cells that had migrated
through the membrane were fixed with methanol and
stained with 0.1% crystal violet (Biotime, China), imaged
and counted using an IX71 inverted microscope (Olympus,
Tokyo, Japan).
Luciferase assays
HO8910pm and SKOV3-ip cells were plated into 24-well
plates until 70% confluence before transfection. 100 ng
wild-type or mutant SphK1 3’-UTR psiCHECK-2 plasmid
(Promega, Madison, WI) was transiently co-transfected
with 60 pmol miR-124 mimics or NC into HO8910pm
and SKOV3-ip cells. Cell lysates were harvested 24 h










MiR-124-RT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCactivities were measured by the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI) on a Berthold
AutoLumat LB9507 rack luminometer. Renilla luciferase
activities were normalized to firefly luciferase activities to
control for transfection efficiency.
Statistical analysis
Data were expressed as the mean ± SD of at least three
independent experiments. Group differences were com-
pared using one-way ANOVA or two-tailed Student’s
T-test from SPSS version 19.0 software (SPSS, Chicago,
IL, USA). p value <0.05 was considered to be statistically
significant.
Results
Reduced expression of miR-124 in highly metastatic
ovarian cancer cell lines and clinical tumors
To determine the expression level of miR-124 in ovarian
cancer progression, we first compared the expression
levels between 13 clinical tumor samples and 2 normalression of miR-124.
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(Figure 1A and Table 1), the results showed that expression
of miR-124 was decreased in 13 cases of ovarian cancer
samples (p < 0.001), compared to normal ovarian tissues.
Furthermore, we examined the expression of miR-124
between five paired metastatic and primary ovarian cancer
tissues. Interestingly, we observed that the expression level
of miR-124 was lower in metastatic tissues than in primary
ovarian cancer samples (p < 0.05) (Figure 1B).
We further detected the abundance of miR-124 in nine
ovarian cancer cell lines. Compared with HOSE (Pricells,
Wuhan, China), a cell derived from human ovary surface
epithelial cells, the expression of miR-124 evaluated by
real time PCR in the above nine ovarian cancer cell lines
were significantly reduced at different extent (Figure 1C),
much lower in SKOV3-ip (Additional file 1) and
HO8910pm [31] cells in particular. These results suggest
that the expression of miR-124 is significantly decreased
in human ovarian cancer specimens and cell lines, which
may be involved in EOC metastasis.
MiR-124 suppresses the migration and invasion of
ovarian cancer cells in vitro
To investigate the functional role of miR-124 in epithelial
ovarian cancer (EOC), we restored miR-124 expression in
SKOV3-ip and HO8910pm cells, which shows the lowest
expression of miR-124 in the nine ovarian cancer cell
lines, by transient transfection with miR-124 mimics or
negative control (NC). To verify the overexpression of
miR-124, stem-loop qRT-PCR was performed and the
results showed significantly increased expression of miR-
124 in SKOV3-ip cells (Additional file 2A). In additionally,
proliferation rate of cells post miR-124 transfection ap-
peared no change (Additional file 3A, B). Given that
SKOV3-ip and HO8910pm are highly metastatic cells, we
then investigated the effect of miR-124 on their migration
and invasion ability. The wound healing assay as well as
migration Transwell assay indicated the ectopic expressionFigure 1 Expression of miR-124 in cell lines and tissues of ovarian c
and ovarian tumors. (B) Comparison of miR-124 expression in five paired
expression level of miR-124 in nine ovarian cancer cell lines. HOSE, the h
Data are presented as means ± SD from three individual experiments. Th
and p < 0.001, respectively.of miR-124 can significantly inhibit cell migration compared
to control group (Figure 2A, B). The same results were
also observed in other two ovarian cancer cell lines, OV90
and OVCAR3 (Additional file 3C, D). Furthermore,
invasion capability of SKOV3-ip and HO8910pm cells
transfected with NC or miR-124 mimics were evaluated
by Matrigel Invasion assay. As expected, the invasion
ability of these two cells was decreased markedly as a
result of overexpression of miR-124 (Figure 2C).
SphK1 is a direct target of miR-124
It is well known that miRNAs regulate gene expression
post transcriptionally by binding to the 3’-UTR of mRNAs.
To verify the target involved in progression of ovarian
cancer, we searched putative target genes via miRanda
and TargetScan and we focused on SphK1 because of its
rank and function associated with migration and invasion,
particularly, the ectopic expression of miR-124 substantially
decreased the expression of SphK1 in both SKOV3-ip and
HO8910pm ovarian cancer cells assessed by western
blot assay (Figure 2D and Additional file 2C), although
real-time PCR analysis did not show obvious changes in
mRNA expression of SphK1 (Additional file 2B). Besides,
we also found that the ovarian cancer samples and meta-
static ovarian cancer tissues showed a high level expres-
sion of SphK1 (Additional file 4A, B). Similarly, a much
higher level expression of SphK1 is also observed in
the SKOV3-ip and HO8910pm cells with high-metastasis
potential showed (Additional file 4C, D). Collectively, the
reduced miR-124 expression and overexpressed SphK1
was probably associated in ovarian cancer tissues and
cells, which indicates that SphK1 was a direct target of
miR-124.
In order to confirm that miR-124 directly targets SphK1,
luciferase assay was performed. SKOV3-ip and HO8910pm
cells were transfected with wild-type full length 3’-UTR of
Sphk1 which was cloned into the psiCHECK™2 Vector as a
control and mutant vector contained 4 mutated bases onancer. (A) Expression of miR-124 in normal human ovarian tissues
primary ovarian tumors and metastatic tissues. (C) The relative
uman normal ovarian epithelial cell line, was used as a control.
e symbols * and *** represent statistical significance at p < 0.05
Figure 2 MiR-124 directly targets SphK1 and inhibits the migration and invasion of ovarian cancer cells. (A) Wound healing
assay of SKOV3-ip and HO8910pm cells transfected with NC or miR-124 mimics. Representative pictures are shown at 0 and 24 h
after the wound was made. (B) Transwell assay of SKOV3-ip and HO8910pm cells transfected with NC or miR-124 mimics.
(C) Matrigel invasion assay of SKOV3-ip and HO8910pm cells transfected with miR-124 mimics or NC. (D) Expression of endogenous
SphK1 in SKOV3-ip cells at 48 h and 72 h post transfection of miR-124 mimics or NC. β-actin was loaded as an internal control.
(E) Diagram of the SphK1-3’-UTR with potential binding-sites for miR-124. (F) Relative luciferase activity of reporters including
wild-type or mutant SphK1 3’-UTR co-transfected with NC or miR-124 mimics. ** and *** indicate significant difference at p < 0.01
and p < 0.001, respectively.
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Additional file 2D upper panel), as well as miR-124 or
NC. Overexpression of miR-124 significantly suppressed
the luciferase activity of reporter genes containing 3’UTR
of SphK1 compared with controls but partially rescued
when the binding site was mutated (Figure 2F and
Additional file 2D lower panel). The results are consis-
tent with previous research [23], indicating that SphK1 is
a predicted target of miR-124, and the inhibitory effect
of miR-124 is due to direct interaction with the putative
binding site of the 3’-UTR of SphK1.Knock-down of SphK1 blocks the migration and invasion
of ovarian cancer cells
To investigate whether MiR-124 has its inhibitory effect
on migration and invasion of ovarian cancer through its
target gene SphK1, we next determined to silence SphK1
and evaluated its expression by western blot in SKOV3-ip
and HO8910pm cells. The silencing of SphK1 was con-
firmed by western blot (Figure 3A). In addition, knock-
down of SphK1 did not affect the proliferation rate of
SKOV3-ip and HO8910pm cells transfected with siRNA
against SphK1 (Additional file 5A, B). Subsequently, we
Figure 3 SphK1 knockdown results in inhibition of migration and invasion in ovarian cancer cells. (A) SphK1 detection in SKOV3-ip and
HO8910pm cells transfected with NC or pooled si-SphK1. (B) Wound healing assay of SKOV3-ip and HO8910pm cells after transfected with NC
or pooled si-SphK1. (C) Transwell assay of SKOV3-ip and HO8910pm cells subjected to NC or pooled si-SphK1. (D) Matrigel invasion assay of
SKOV3-ip and HO8910pm cells after transfection with NC or pooled si-SphK1. Symbols ** and *** represent significance at p < 0.01 and
p < 0.001, respectively.
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transfected with pooled siRNA fragments, migration
and invasion were suppressed (Figure 3B, C and D). These
results suggest that SphK1 participates in the motility of
ovarian cancer cells.
Expression of SphK1 reversed the miR-124-induced
inhibition of cellular migration and invasion
In order to investigate the contribution of SphK1 to
cellular migration and invasion, we ectopically expressed
SphK1 together with miR-124 in SKOV3-ip cells to evalu-
ate whether this may overcome the suppressive effect of
miR-124 on cell migration and invasion. The SKOV3-ip
cells were co-transfected with NC or miR-124 together
with pCDNA3.1 (−)-vector or pCDNA3.1 (−)-SphK1 for
48 h. The expression of SphK1 recovered after SphK1
transfection (Figure 4A). Migration and invasion assays
showed that enforced expression of SphK1 reversed
miR-124-induced inhibition of migration and invasion
(Figure 4B, C). Collectively, our results indicate that
miR-124 participates in SphK1-mediated migration and
invasion of EOC cells, suggesting that SphK1 is a func-
tional mediator of miR-124 in EOC metastasis.
Discussion
In the present study, we found that miR-124 was down-
regulated in ovarian cancer cell lines and tumor tissuescompared with normal ovarian surface epithelial cells and
normal ovarian tissues. Furthermore, we showed that
miR-124 inhibited EOC cell migration and invasion,
which may be involved in the development of ovarian
cancer metastasis. We also demonstrated that SphK1 is
a direct target of miR-124 in EOC. Therefore, we now
reasonably speculate that low expression of miR-124
contributes to SphK1-mediated migration in EOC cells.
Increasing evidence suggests to us that miRNAs are
frequently dysregulated in various cancers, including
ovarian cancer [3,5]. In this study, we observed that the
expression level of miR-124 was low in ovarian cancer
tissues, and even lower in the metastatic ovarian tissues.
The abnormal expression of miRNAs in ovarian cancer
has been previously evaluated [6,14,32]. In agreement
with our results, Iorio et al. [2] have demonstrated that
miR-124a is down-regulated in ovarian cancer tissues
compared with normal ovarian samples. However, the
role of miR-124 in ovarian cancer has not been reported
in ovarian cancer [14,33]. Additionally, the directionality
of expression of miR-124 (down-regulated) and SphK1
(up-regulated) that we observed appeared to be definitive
in the two high-metastasis potential ovarian cancer cell
lines, SKOV3-ip and HO8910pm. Also, clinical ovarian
cancer samples were used to confirm the relationship
between the endogenous expression levels of SphK1 and
miR-124. In essence, this provided the possibility that
Figure 4 Expression of SphK1 reversed the miR-124-induced inhibition of cellular migration and invasion. (A) The transfection of
pcDNA3.1 (−)–SphK1 restored the expression of Sphk1 in SKOV3-ip cells even with miR-124 co-transfection. (B) Transwell assay and (C) Matrigel
invasion assay of SKOV3-ip cells after co-transfection of NC or miR-124 mimics together with either pcDNA3.1 (−)-vector or pcDNA3.1 (−)-SphK1.
***denotes statistical significance at p < 0.001.
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and invasion in ovarian cancer.
Invasion and metastasis are two leading attributes of
malignant cancer [34] that result in high mortality in
EOC. Our findings emphasize that the miRNA-induced
down-regulation of genes may lead to the inhibition
of migration and invasion of ovarian cancer cells, in
agreement with several previous reports [20,21,35]. Al-
though it has been reported that miR-124 is functionally
involved in gynecological cancer [36], to the best of our
knowledge, there are no published data on the role of
miR-124 regarding migration and invasion in EOC. In this
context, our study indicates that miR-124, by targeting
SphK1, inhibits migration and invasion of ovarian cancer
cells, suggesting that miR-124 plays a key role as a tumor
suppressor in the motility of ovarian cancer cells; and
that reduced expression of SphK1 contributes to distant
metastases in EOC.
It is important to note that one microRNA can exert
different functions by targeting multiple mRNAs[37]; that
is, other genes regulated by miR-124 may also lead to
ovarian carcinogenesis. Overexpression of miR-124 in-
hibits aggressiveness of hepatocellular carcinoma cell bytargeting ROCK2 and EZH2[21]. Additionally, Fowler
et al. reported that IQGAP1, laminin c1 and integrin b1
(which are not the only 3 targets of miR-124) are also
associated with migration and invasion in clinical glioblast-
oma specimens, compared with normal brain tissue [38].
In addition, We confirmed through luciferase reporter
gene assays that miR-124 directly targets SphK1 by binding
the 3’-UTR of SphK1 mRNA, which is consistent with
Xia et al. [23]. MiR-124 blocks migration and invasion
of ovarian cancer cells by targeting SphK1, which would
constitute a promising target for rational cancer therapy.
Also, our results provided another mechanism for modulat-
ing the protein expression of SphK1 in ovarian cancer cells.
Thus, it is possible that miR-124 could attenuate EOC
invasion partly through inhibition of the SphK1pathway.
Conclusions
In conclusion, our current study provides novel evidence
that ectopic expression of miR-124 significantly suppresses
migration and invasion of ovarian cancer cells and down-
regulates SphK1, which is a direct functional target of
miR-124. The loss of miR-124 may then contribute to the
migration and invasion of EOC cells. The newly identified
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metastasis of EOC, especially with respect to invasion
and metastasis in vitro; and represents a new potential
therapeutic target for the treatment of EOC.
Additional files
Additional file 1: Ovarian cancer subline SKOV3-ip with high
metastatic capacity. Matrigel invasion assay showed the invasive ability
of was about 4-fold greater than the parent cell line SKOV3 (P < 0.05).
Additional file 2: Validation of miR-124 targeting SphK1 in
HO8910pm cells. (A) Detection of miR-124 expression in SKOV3-ip cells
after transfection with NC or miR-124 mimics. (B) Ectopic expression of
miR-124 does not affect SphK1 mRNA in SKOV3-ip cells. (C) Immunoblotting
of endogenous SphK1 expression in HO8910pm cells transfected with
NC or miR-124 mimics. (D) Upper panel: Schematic representation of the
luciferase reporter constructs. Lower panel: luciferase reporter assay
performed in HO8910pm cells.
Additional file 3: Overexpression of miR-124 has no effects on
proliferation but suppresses the motility of cells. (A), (B) miR-124
overexpression does not affect cell proliferation of SKOV3-ip and
HO8910pm cells. (C) Transwell migration assay of OV90 and OVCAR3 cells
transfected with NC or miR-124 mimics. (D) Matrigel invasion assay of
OV90 and OVCAR3 cells transfected with NC or miR-124 mimics. Both cell
lines transfected with 100 nM miR-124 mimics or NC were inoculated in
6- well plates at 24 h. CCK-8 assay was performed at 48 h and 72 h after
transfection.
Additional file 4: Expression of SphK1 in ovarian cancer cell lines
and clinical ovarian cancer samples. (A) Expression levels of SphK1 in
normal tissue and ovarian cancer tissues. (B) Comparison of
SphK1expression in five paired primary ovarian tumors and metastatic
tissues. (C) Expression of SphK1 in the human normal ovarian epithelial
cell line (HOSE) and nine ovarian cancer cell lines. (D) Western blot of
SphK1 protein expression in nine ovarian cancer cells.
Additional file 5: Knock-down SphK1 has no effects on proliferation
of SKOV3-ip and HO8910pm cells. (A), (B) pooled Si-SphK1transfection
does not affect cell proliferation of SKOV3-ip and HO8910pm cells.
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